SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brian Malloy who wrote (574)5/5/1998 12:29:00 AM
From: billkirn  Read Replies (1) of 2135
 
All: I believe AGPH's AG3340 is far ahead of this candidate, entering phase III trials now so don't bet you life here.

"Agouron's Matrix Mettalloprotease (MMP)- AG3340 is directly anti-angiogenic. Phase III clinical trials were started at the end of the last quarter (March, 98). AG3340 will be an oral pill, as opposed to Entremeds which needs to be injected. AG3340 is a small synthetic molecule."
full link, Message 4318324
After the public learns more and does some dudil. this baby could come down pretty hard.
Bill

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News